315 related articles for article (PubMed ID: 23280874)
21. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
Glaffig M; Palitzsch B; Hartmann S; Schüll C; Nuhn L; Gerlitzki B; Schmitt E; Frey H; Kunz H
Chemistry; 2014 Apr; 20(15):4232-6. PubMed ID: 24623572
[TBL] [Abstract][Full Text] [Related]
22. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2.
Kaiser A; Gaidzik N; Becker T; Menge C; Groh K; Cai H; Li YM; Gerlitzki B; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2010 May; 49(21):3688-92. PubMed ID: 20449837
[No Abstract] [Full Text] [Related]
23. Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.
Sungsuwan S; Yin Z; Huang X
ACS Appl Mater Interfaces; 2015 Aug; 7(31):17535-44. PubMed ID: 26200668
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
Glaffig M; Stergiou N; Schmitt E; Kunz H
ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
[TBL] [Abstract][Full Text] [Related]
25. Synthetic glycopeptides for the development of cancer vaccines.
Liakatos A; Kunz H
Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
[TBL] [Abstract][Full Text] [Related]
26. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L
Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174
[TBL] [Abstract][Full Text] [Related]
28. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
[No Abstract] [Full Text] [Related]
29. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin.
Dziadek S; Kowalczyk D; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7624-30. PubMed ID: 16247814
[No Abstract] [Full Text] [Related]
30. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.
Liu Y; Zhang W; He Q; Yu F; Song T; Liu T; Zhang Z; Zhou J; Wang PG; Zhao W
Chem Commun (Camb); 2016 Sep; 52(72):10886-9. PubMed ID: 27530357
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.
McDonald DM; Hanna CC; Ashhurst AS; Corcilius L; Byrne SN; Payne RJ
ACS Chem Biol; 2018 Dec; 13(12):3279-3285. PubMed ID: 30359529
[TBL] [Abstract][Full Text] [Related]
32. CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines.
Hartmann S; Nuhn L; Palitzsch B; Glaffig M; Stergiou N; Gerlitzki B; Schmitt E; Kunz H; Zentel R
Adv Healthc Mater; 2015 Mar; 4(4):522-7. PubMed ID: 25327631
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of tumor-associated glycopeptide antigens for the development of tumor-selective vaccines.
Dziadek S; Kunz H
Chem Rec; 2004; 3(6):308-21. PubMed ID: 14991920
[TBL] [Abstract][Full Text] [Related]
35. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
36. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
[No Abstract] [Full Text] [Related]
37. [Recent advance in carbohydrate-based cancer vaccines].
Huo CX; Ye XS
Yao Xue Xue Bao; 2012 Mar; 47(3):261-70. PubMed ID: 22645748
[TBL] [Abstract][Full Text] [Related]
38. Covalent bond or noncovalent bond: a supramolecular strategy for the construction of chemically synthesized vaccines.
Gao Y; Sun ZY; Huang ZH; Chen PG; Chen YX; Zhao YF; Li YM
Chemistry; 2014 Oct; 20(42):13541-6. PubMed ID: 25155367
[TBL] [Abstract][Full Text] [Related]
39. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
[TBL] [Abstract][Full Text] [Related]
40. Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues.
Wagner S; Mersch C; Hoffmann-Röder A
Chemistry; 2010 Jun; 16(24):7319-30. PubMed ID: 20461825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
